The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer
Cell Proliferation2020Vol. 53(3), pp. e12770–e12770
Citations Over TimeTop 10% of 2020 papers
Abstract
Preferentially expressed antigen in melanoma (PRAME), which belongs to the cancer/testis antigen (CTA) gene family, plays a pivotal role in multiple cellular processes and immunotherapy response in human cancers. PRAME is highly expressed in different types of cancers and is involved in cell proliferation, apoptosis, differentiation and metastasis as well as the outcomes of patients with cancer. In this review article, we discuss the potential roles and physiological functions of PRAME in various types of cancers. Moreover, this review highlights immunotherapeutic strategies that target PRAME in human malignancies. Therefore, the modulation of PRAME might be useful for the treatment of patients with cancer.
Related Papers
- → B7-H3/CD276: An Emerging Cancer Immunotherapy(2021)282 cited
- → pH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review(2020)95 cited
- → A Novel Function of Junctional Adhesion Molecule-C in Mediating Melanoma Cell Metastasis(2011)88 cited
- → Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators(2020)80 cited
- → MicroRNA-138 negatively regulates the hypoxia-inducible factor 1α to suppress melanoma growth and metastasis(2019)23 cited